The Identification of GPR52 Agonist HTL0041178, a Potential Therapy for Schizophrenia and Related Psychiatric Disorders
- ACS Med Chem Lett. 2023 Mar 14;14(4):499-505. doi: 10.1021/acsmedchemlett.3c00052.
- 1. Sosei Heptares, Steinmetz Building, Granta Park, Great Abington, Cambridge CB21 6DG, United Kingdom.
- 2. Syngene International, Biocon Park, Bommasandra, Bangalore 560099, India.
HTL0041178 (1), a potent GPR52 agonist with a promising pharmacokinetic profile and exhibiting oral activity in preclinical models, has been identified. This molecule was the outcome of a judicious molecular property-based optimization approach, focusing on balancing potency against metabolic stability, solubility, permeability, and P-gp efflux.
-
Cat. No.Product NameDescriptionTargetResearch Area
-
target: GPR52Research Areas: Neurological Disease